Literature DB >> 1151134

Diminished erythroid ferrochelatase activity in protoporphyria.

S S Bottomley, M Tanaka, M A Everett.   

Abstract

In two patients with protoporphyria the enzymatic synthesis of aminolevulinic acid and prophobilinogen in erythroid tissue was normal. Boine marrow ferrochelatase activity was less than one-fourth of the mean activity in normal control subjects. Ferrochelatase activity in peripheral blood reticulocytes was less than 10% of controls. This metabolic abnormality provides one biochemical explanation for the increased concentrations of blood protoporphyrin in protoporphyria and clarifies the apparent minimally impaired hemoglobin synthesis in the two case studies.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1151134

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  32 in total

1.  Strong correlation of ferrochelatase enzymatic activity with Mitoferrin-1 mRNA in lymphoblasts of patients with protoporphyria.

Authors:  John Phillips; Collin Farrell; Yongming Wang; Ashwani K Singal; Karl Anderson; Manisha Balwani; Montgomery Bissell; Herbert Bonkovsky; Toni Seay; Barry Paw; Robert Desnick; Joseph Bloomer
Journal:  Mol Genet Metab       Date:  2018-10-22       Impact factor: 4.797

2.  Molecular defects in ferrochelatase in patients with protoporphyria requiring liver transplantation.

Authors:  J Bloomer; C Bruzzone; L Zhu; Y Scarlett; S Magness; D Brenner
Journal:  J Clin Invest       Date:  1998-07-01       Impact factor: 14.808

3.  The molecular defect of ferrochelatase in a patient with erythropoietic protoporphyria.

Authors:  Y Nakahashi; H Fujita; S Taketani; N Ishida; A Kappas; S Sassa
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205

Review 4.  Erythropoietic protoporphyria.

Authors:  T M Cox
Journal:  J Inherit Metab Dis       Date:  1997-06       Impact factor: 4.982

5.  Study of factors causing excess protoporphyrin accumulation in cultured skin fibroblasts from patients with protoporphyria.

Authors:  J R Bloomer; D A Brenner; M J Mahoney
Journal:  J Clin Invest       Date:  1977-12       Impact factor: 14.808

Review 6.  Heme biosynthesis and the porphyrias.

Authors:  John D Phillips
Journal:  Mol Genet Metab       Date:  2019-04-22       Impact factor: 4.797

7.  Blood cells as markers for metabolic disorders.

Authors:  E Beutler
Journal:  Blut       Date:  1985-12

Review 8.  The ferrochelatase gene structure and molecular defects associated with erythropoietic protoporphyria.

Authors:  S Taketani; H Fujita
Journal:  J Bioenerg Biomembr       Date:  1995-04       Impact factor: 2.945

9.  Variable effects of beta-carotene therapy in a child with erythropoietic protoporphyria.

Authors:  Ramin Alemzadeh; Tammy Feehan
Journal:  Eur J Pediatr       Date:  2004-07-06       Impact factor: 3.183

Review 10.  Enzymatic defects of hereditary porphyrias: an explanation of dominance at the molecular level.

Authors:  G Romeo
Journal:  Hum Genet       Date:  1977-12-23       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.